Category
Applied
Description
Monoclonal antibodies are currently one of the most effective tools in biomedical research, diagnostics and therapeutic development. Hybridoma technique, which involves the fusion of immortal myeloma cells with stimulated B cells to produce an infinite supply of monoclonal antibodies. A stock of antibodies produced from offspring of a single hybridoma cells is the best way of producing monoclonal antibodies. These hybridoma cultures produce antibodies that are specific to a single target, or antigen. The targets for these monoclonal antibodies are almost limitless and can include enzymes, hormones, internal structures on bacteria, viruses and other eukaryotic cells as well as receptors.
Based on their unique properties of specificity and strong affinity for targets, monoclonal antibodies can be engineered to activate a receptor (agonist) or block the receptor from receiving a signal (antagonist) when bound. This has led to the development of several diagnostics tools in biomedical research including ELISA, fluorescence microscopy, flow cytometry and various rapid diagnostic test (RDT) kits for diagnostic purposes. In medicine, monoclonal antibodies have been used to formulate various drugs including denosumab which has significantly changed the management of osteoporosis with positive outcomes.
Since Kohler and Milstein described the method for generating hybridomas in 1975, they have become the preeminent technique for monoclonal (single target) antibody production in academic and clinical research, perhaps, due to the long shelf life of hybridoma cells in cryopreservation which ensures reproducibility at any point in time. Additionally, this technique is convenient, and cost effective compared to other methods such as Recombinant DNA Technology and Single B cell Technology.
The aim of the current study, therefore, is to explore the hybridoma technology for antibody production by fusing immortal SP2/0 Ag14 myeloma cells with mouse B cells, purified from the spleens of Balb/c mice. These mice were stimulated with purified ovalbumin (OVA) for four consecutive weeks prior to sacrifice to stimulate OVA – reactive B cells. This study will establish a local protocol for the production of monoclonal antibodies to other targets using the hybridoma technique.
Establishing Local Protocols for Monoclonal Antibodies Production Using Hybridomas
Applied
Monoclonal antibodies are currently one of the most effective tools in biomedical research, diagnostics and therapeutic development. Hybridoma technique, which involves the fusion of immortal myeloma cells with stimulated B cells to produce an infinite supply of monoclonal antibodies. A stock of antibodies produced from offspring of a single hybridoma cells is the best way of producing monoclonal antibodies. These hybridoma cultures produce antibodies that are specific to a single target, or antigen. The targets for these monoclonal antibodies are almost limitless and can include enzymes, hormones, internal structures on bacteria, viruses and other eukaryotic cells as well as receptors.
Based on their unique properties of specificity and strong affinity for targets, monoclonal antibodies can be engineered to activate a receptor (agonist) or block the receptor from receiving a signal (antagonist) when bound. This has led to the development of several diagnostics tools in biomedical research including ELISA, fluorescence microscopy, flow cytometry and various rapid diagnostic test (RDT) kits for diagnostic purposes. In medicine, monoclonal antibodies have been used to formulate various drugs including denosumab which has significantly changed the management of osteoporosis with positive outcomes.
Since Kohler and Milstein described the method for generating hybridomas in 1975, they have become the preeminent technique for monoclonal (single target) antibody production in academic and clinical research, perhaps, due to the long shelf life of hybridoma cells in cryopreservation which ensures reproducibility at any point in time. Additionally, this technique is convenient, and cost effective compared to other methods such as Recombinant DNA Technology and Single B cell Technology.
The aim of the current study, therefore, is to explore the hybridoma technology for antibody production by fusing immortal SP2/0 Ag14 myeloma cells with mouse B cells, purified from the spleens of Balb/c mice. These mice were stimulated with purified ovalbumin (OVA) for four consecutive weeks prior to sacrifice to stimulate OVA – reactive B cells. This study will establish a local protocol for the production of monoclonal antibodies to other targets using the hybridoma technique.
